CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Cardoz AB
ClinicalTrials.gov Identifier:
NCT01540604
First received: February 23, 2012
Last updated: October 1, 2012
Last verified: October 2012

February 23, 2012
October 1, 2012
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01540604 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
An Open-label, Un-controlled, Single-centre Trial Investigating the Efficacy and Safety of CRD007 in Children With Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD) or Children Being Symptomatic Carriers for DMD or BMD

This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.

Not Provided
Interventional
Phase 2
Not Provided
  • Duchenne Muscular Dystrophy
  • Becker Muscular Dystrophy
Drug: CRD007
Experimental: CRD007 10 mg tablet
Intervention: Drug: CRD007
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Documented diagnosis of dystrophinopathy

Exclusion Criteria:

  • Severe functional impairment
Both
2 Years to 11 Years
Not Provided
Contact information is only displayed when the study is recruiting subjects
Sweden
 
NCT01540604
Cardoz-004
Not Provided
Cardoz AB
Cardoz AB
Not Provided
Principal Investigator: T Sejersen, MD PhD Karolinska University Hospital
Cardoz AB
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP